New horizons in treatment of osteoporosis.
Tabatabaei-Malazy O, Salari P, Khashayar P, Larijani B.
Tabatabaei-Malazy O, et al.
Daru. 2017 Feb 7;25(1):2. doi: 10.1186/s40199-017-0167-z.
Daru. 2017.
PMID: 28173850
Free PMC article.
Review.
In addition, they have potential adverse events on long time usage. Development of newer agents such as cathepsin k inhibitor and strontium ranelate not only have increased the available options for treating osteoporosis, but also have opened doors of opportunity to improv …
In addition, they have potential adverse events on long time usage. Development of newer agents such as cathepsin k inhibitor and str …